Post-earnings recap
Reported
Wed, Nov 6, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Alnylam Pharmaceuticals is struggling to meet earnings expectations, which has led to a negative stock reaction of 4.1%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance and strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -27.32% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern over the current financial performance. They highlighted the need for strategic adjustments moving forward.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting EPS expectations.